白血病患者血浆白细胞介素18的水平及其临床意义

本研究探讨白血病患者血浆白细胞介素 18(IL 18)水平与白血病发病、预后及治疗的相关临床意义。采用酶联免疫吸附测定法 ,对 3 7例白血病患者在初诊时及化疗后 2周分别采集静脉血 ,测定其血浆IL 18水平 ,以18名献血员为正常对照组。结果显示 ,白血病患者血浆IL 18水平治疗前略高于正常水平 ,但差异无显著性。其中急性淋巴细胞白血病患者血浆IL 18水平升高显著 (173 2 7± 3 4 2 4pg/ml) ,慢性粒细胞性白血病患者IL 18水平 (111.82± 50 .56pg/ml)低于正常对照组 (13 5.82± 47.0 0pg/ml)。化疗后 ,白血病各组患者血浆IL 18水平均明显低于正常对照组 (P <0 0 0 1)。结论 :白血病患者血浆IL 18水平是不均一性的 ,而其化疗后血浆IL 18水平均明显减低。这一点预示着白血病患者化疗后的免疫功能低下与其血浆IL 18水平下降 ,以致其相关联的一系列细胞因子的相应减少有关

Alteration of Plasma Interleukin-18 Level in Leukemia Patients and Its Clinical Significance

To explore the alteration of plasma level of IL-18 in patients with leukemia before and after chemotherapy and its clinical significance, the plasma level of IL-18 was determined with ELISA method before and 2 weeks after chemotherapy in 37 leukemia patients, and 18 normal individuals. The results showed that the plasma IL-18 level (153.34 +/- 50.74 pg/ml) in leukemia patients was similar to the level (135.82 +/- 47.00 pg/ml) in normal control, and the IL-18 level in ALL patients was significantly increased (173.3 +/- 34.4 pg/ml), while the IL-18 level in CML patients (111.8 +/- 50.5 pg/ml) was lower than normal level. After chemotherapy, the IL-18 level (100.89 +/- 50.07 pg/ml) was significantly lower than normal level and oneself before treatment. It is concluded that plasma IL-18 levels in leukemia patients are un-homogeneous and IL-18 production decreased after chemotherapy, and immunologic hypofunction in patients with chemotherapy might be related with the decrease of IL-18 and related cytokines.